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Neglected Diseases
I
n the early part of the twentieth century, human African 
trypanosomiasis (HAT), also known as sleeping sickness, 
decimated the population in many parts of sub-Saharan 
Africa. In the 1930s, the colonial administrations, conscious 
of the negative impact of the disease on its territories, 
established disease control programmes. Systematic 
screening, treatment, and follow-up of millions of individuals 
in the whole continent led to transmission coming to a near 
halt by the 1960s. 
With the advent of independence in most countries where 
HAT was endemic, the newly independent authorities had 
other priorities to deal with. The rarity of HAT cases, and a 
decline in awareness of how the disease could return, led to a 
lack of interest in disease surveillance. Over time the disease 
slowly returned, and some thirty years later, ﬂare-ups were 
observed throughout past endemic areas (Figure 1).
Since 1995, the World Health Organization (WHO) has 
on many occasions expressed its concern about the rise in 
HAT cases. The World Health Assembly has passed several 
resolutions in an attempt to stem this rise. However, social 
upheavals, wars, and population movements, combined 
with lack of awareness and shortage of funds, prevented 
any progress in interrupting transmission, and the disease 
continued to evolve and spread.
In a 1997 resolution, WHO strongly advocated access 
to diagnosis and treatment and the reinforcement of 
surveillance and control activities, concurrently setting up a 
network to strengthen coordination among all those actively 
concerned by the problem [1]. As a consequence, the 
public and private sector granted stronger support to HAT 
surveillance, control, and research.
Pathology, Clinical Features, and Epidemiology
HAT is a vector-borne parasitic disease that is fatal if left 
untreated. It is caused by a single-celled protozoa belonging 
to the Trypanosoma genus. Parasites are transmitted to humans 
by the bite of a tsetse ﬂy (Glossina genus) that has acquired 
the infection from human beings or from animals harbouring 
the human pathogenic parasites (Figure 2).
Tsetse ﬂies, and subsequently sleeping sickness, are usually 
found in remote sub-Saharan rural areas where health 
systems are weak or non-existent. For reasons that are so far 
unexplained, there are many regions where tsetse ﬂies are 
found but sleeping sickness is not. Sleeping sickness, coupled 
with nagana, the animal form of African trypanosomiasis, 
has been a major obstacle to sub-Saharan African rural 
development and a stumbling block to agricultural production. 
On the one hand, human infections reduce labour resources, 
while on the other, the animal disease limits availability of 
meat and milk and deprives African farmers of draught animal 
power, substantially minimising crop production. Therefore, 
both human and animal trypanosomiasis are implicated 
in the underdevelopment of the African continent, and 
are considered a major obstacle in the establishment of a 
ﬂourishing agriculture to provide food security and to lead to 
sustainable economic growth and healthy populations.
The rural populations that live in regions where 
transmission occurs and depend on agriculture, ﬁshing, 
animal husbandry, or hunting are the most exposed to 
the bite of the tsetse ﬂy and therefore to the disease. 
Displacement of populations, war, and poverty are important 
factors leading to increased transmission. The disease 
develops in areas whose size can range from a village to an 
entire region. Within a given area, the intensity of the disease 
can vary from one village to the next.
The human disease takes two forms, depending on the 
parasite involved. Trypanosoma brucei gambiense is found in 
west and central Africa. This form represents more than 
90% of reported cases of sleeping sickness, and causes a 
chronic infection. A person can be infected for months or 
even years without major signs or symptoms of the disease. 
When symptoms do emerge—such as severe headaches, 
sustained fever, sleep disturbances, alteration of mental state, 
and neurological disorders—the patient is often already 
in an advanced disease stage where the central nervous 
system is affected. Trypanosoma brucei rhodesiense is found 
in eastern and southern Africa. This form represents less 
than 10% of reported cases, and causes an acute infection. 
The ﬁrst signs and symptoms—such as chancre, occasional 
headaches, irregular fevers, pruritus, and the development 
of adenopathies—are observed after a few weeks or months. 
Following this ﬁrst stage, when the parasite has invaded the 
blood and lymph subsequent to the infective bite of the 
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ﬂy, the disease develops rapidly into a second stage when 
parasites cross the blood–brain barrier, invading the central 
nervous system.
Thirty-six sub-Saharan countries are considered endemic 
for one or the other form of the disease, despite the fact 
that some of them have reported no cases in the last decade 
(Figure 3).
Current Situation
Since WHO expressed its concerns in 1995, there have 
been great improvements in HAT control. In addition to 
political will at the highest levels, capacities for control and 
surveillance in endemic countries were strengthened through 
training and the provision of equipment for screening, 
diagnosis, and treatment. 
The abatement of social upheavals and civil wars in many 
countries where HAT was endemic facilitated access to 
diagnosis and treatment, which was then enhanced by the 
ﬁnancial and technical support from WHO for outreach 
activities, and by securing production and free distribution of 
drugs. Between 1995 and 2006, the total number of new cases 
reported was reduced by 68%. 
With WHO support and commitment, it became possible 
to reinforce exhaustive screening of the population at risk, 
using a combination of immunological and parasitological 
tests. The card agglutination test for trypanosomiasis (CATT) 
developed in 1978 is widely used for screening the population 
affected by T. b. gambiense, but is not applicable in T. b. 
rhodesiense areas. CATT-positive results are not sufﬁciently 
sensitive and speciﬁc to establish a deﬁnitive diagnosis, and 
therefore parasitological tests must be performed to conﬁrm 
the presence of parasites in seropositive individuals. Such tests 
consist of microscopic examination of the lymph and blood. 
They are considered cumbersome and insufﬁciently sensitive 
to ascertain absence of infection [2]. Diagnosis is followed by 
systematic stage determination, which consists of assessing the 
cerebrospinal ﬂuid for white blood cell increases, elevated 
protein concentrations, and the presence of parasite—thus 
requiring a lumbar puncture, an invasive procedure that is 
not well accepted by patients.
Treatment today relies on four parenteral drugs: suramin 
for ﬁrst-stage rhodesiense, pentamidine for ﬁrst-stage gambiense,
melarsoprol for the second stage of both forms of the disease, 
and eﬂornithine, which is only effective in the second stage of 
the gambiense form. The management of patients using any of 
these drugs is cumbersome and risky, requiring well-trained 
staff.
Despite success in reducing the number of cases reported, 
the complexity of the current tools available to control the 
disease does not allow the full involvement of the health care 
system, hampering the sustainability of HAT surveillance and 
control as discussed below.
doi:10.1371/journal.pmed.0050055.g001
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Epidemiological update. In early 2006, WHO published an 
update on the disease situation and ongoing control activities 
in each of the 36 countries considered endemic for HAT [3]. 
The two forms of the disease were considered separately, due 
to their different epidemiological characteristics. 
Between 1997 and 2006, the gambiense form (97% of the 
total cases reported at continental level) responded well to 
intensive control activities mainly focused on the human 
reservoir (the animal reservoir was considered to have only a 
minor impact on the transmission process). The number of 
people under active surveillance increased, and the number of 
new cases decreased (Table 1 and Figure 4). However, control 
activities focusing on the human T. b. rhodesiense reservoir (3% 
of the total number of cases reported) were found insufﬁcient 
to control the disease, probably due to the role played by the 
animal reservoir on transmission. Thus, T. b. rhodesiense showed 
only a small decrease in the number of cases (Table 2).
Out of 36 countries considered endemic for HAT, 24 are 
experiencing T. b. gambiense transmission. In these countries, 
there was a 69% reduction in the number of new cases 
reported during the period from 1997–2006. In 2006, 11 out 
of the 24 countries reported no cases; six of them had no 
control activities and reported no cases over a decade; and 
the other ﬁve implementing control activities reported only 
sporadic cases during the 1997–2004 period. Together, the 
cases in these 11 countries represent only 0.1% of the total 
gambiense cases reported.
Six countries reported an average of less than 100 new 
cases per year, representing 1.2% of the total gambiense
cases. All these countries (except Nigeria) have National 
Sleeping Sickness Control Programmes and carry out regular 
control activities. Four countries, with well-established 
Control Programmes and regular control activities, have 
reported more than 100 but less than 1,000 new cases per 
year, representing 8.8% of the total gambiense cases reported. 
Finally, three countries have reported an average of more 
than 1,000 new cases per year during the period from 1997–
2006; together they represent 89.9% of the total gambiense
cases reported (Table 1).
In the 13 countries endemic for rhodesiense, there was a 21% 
reduction in the number of new cases reported during the 
1997–2006 period (Table 2). However, only Kenya, Malawi, 
Tanzania, and Uganda implemented control activities (since 
Uganda is affected by both forms of the disease, the country 
appears in Tables 1 and 2). Out of these 13 countries, ﬁve 
reported no cases over a decade and four reported sporadic 
cases. Together, these four countries reporting only sporadic 
cases represent 2.5% of the total rhodesiense cases reported 
during the 1997–2006 period. Two countries reported an 
average of less than 100 new cases per year, representing 
8.7% of the total rhodesiense cases, and two reported more 
than 100 but less than 1,000 new cases per year, representing 
88.8% of the rhodesiense cases reported.
The road to elimination. To achieve the 1997 World 
Health Assembly elimination resolution [1], the WHO HAT 
Surveillance and Control Programme established a new 
initiative based on a global alliance bringing together all 
actors concerned about the disease [4]. In 2003, the World 
Table 1. T. b. gambiense Sleeping Sickness: New Cases Reported between 1997 and 2006
Countries 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
More than 1,000 new cases per year
Angola 8,275 6,610 5,351 4,546 4,577 3,621 3,115 2,280 1,727 1,105
DRC 25,094 26,318 18,684 16,975 17,322 13,853 11,481 10,369 10,269 8,023
Sudan 737 1,726 1,312 1,609 1,804 3,163 3,076 1,766 1,869 809
More than 100 but less than 1,000 new cases per year
Chad 122 134 187 153 138 715 222 483 190 276
CAR 730 1068 869 988 717 570 538 737 666 460
Congo 142 201 91 111 894 1005 682 859 398 300
Uganda 1123 971 1036 1141 424 562 501 354 304 270
Less than 100 new cases per year 
Cameroon 10 54 32 27 13 32 33 17 3 15
Côte d’Ivoire 185 121 104 169 84 92 51 72 40 29
Equatorial Guinea 67 62 28 16 17 32 23 22 17 13
Gabon 11 6 38 45 30 25 26 48 53 31
Guinea 88 99 68 52 72 124 116 84 94 48
Nigeria 0 0 27 14 14 26 31 10 21 3
No new cases with control activities present
Benin 0 0 20 72 83 8 3 0 0 0
Burkina Faso 1 15 15 8 8 2 3 2 0 0
Ghana 0 0 0 1 0 0 0 0 0 0
Mali 0 0 0 18 3 2 0 0 0 0
Togo 0 0 0 0 0 0 0 0 0 0
No new cases and no control activities
Gambia nd nd nd nd nd nd nd nd nd nd
Guinea Bissau nd nd nd nd nd nd nd nd nd nd
Liberia nd nd nd nd nd nd nd nd nd nd
Niger nd nd nd nd nd nd nd nd nd nd
Senegal nd nd nd nd nd nd nd nd nd nd
Sierra Leone nd nd nd nd nd nd nd nd nd nd
Total 36,585 37,385 27,862 25,945 26,200 23,832 19,901 17,103 15,651 11,382
CAR, Central African Republic; DRC, Democratic Republic of the Congo; nd, no data reported
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Health Assembly called on member states to sustain the 
effort to eliminate the disease as a public health problem, 
which led the WHO programme to intensify its coordinating 
efforts, bringing together national control programmes, non-
governmental organisations, research institutions, and other 
concerned United Nations Agencies (under the Programme 
against African Trypanosomiasis, PAAT) [5], as well as private 
and public contributors (Sanoﬁ-Aventis, Bayer HealthCare, 
the Bill & Melinda Gates Foundation, and the Belgium 
and French Cooperation). With this broad coalition, ﬁeld 
activities were scaled up, leading to better knowledge of the 
disease distribution and a reduction in new cases by 2006, 
as described above. The current prevalence and incidence 
ﬁgures are believed to reﬂect the overall situation quite 
accurately, in contrast with the uncertainties surrounding the 
ﬁgures prior to 1997.
Given that in 2006, 20 out of 36 endemic countries 
achieved or were close to achieving the target of reporting 
no new cases, and eight countries reported less than 100 new 
cases per year, elimination has become a feasible objective in 
many countries endemic for HAT. With elimination in mind, 
in May 2007 WHO organised an Informal Consultation on 
Sustainable Sleeping Sickness Control, during which endemic 
country representatives debated the current disease landscape 
and concluded that elimination was possible.
Political will. During the July 2000 Organization of African 
Unity (now the African Union) summit held in Lomé, 
Togo, the African Heads of State and Government adopted 
the decision to collectively embark on a Pan African Tsetse 
and Trypanosomosis Eradication Campaign (PATTEC). 
This campaign was based on the realisation that (1) solving 
the tsetse ﬂy and disease problem would be an important 
contribution to Africa’s development, and (2) this could 
not be done by a single country acting alone. A task force of 
African experts concluded that such a campaign was not only 
technically feasible, but economically productive [6]. 
Implementation is on its way; six countries have recently 
received ﬁnancial support from the African Development 
doi:10.1371/journal.pmed.0050055.g002
Figure 2. HAT Transmission Cycle
In T. b. gambiense, the cycle is mostly human-to-human (central circle); occasionally transmission may occur from animal to human. In T. b. rhodesiense,
the animal reservoir plays an important role in the cycle, thus sustaining parasite transmission and human infections.
Table 2. T. b. rhodesiense Sleeping Sickness: New Cases Reported between 1997 and 2006
Countries 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
More than 100 but less than 1,000 new cases per year
Tanzania 354 299 288 347 258 226 111 157 183 125
Uganda 217 283 283 266 426 328 321 318 479 245
Less than 100 new cases per year
Malawi 7 10 11 35 38 43 70 47 41 58
Zambia nd nd 15 9 6 17 7 35 20 57
Sporadic new cases
Kenya 5 14 22 12 14 13 0 0 0 1
Mozambique nd nd nd nd nd 1 nd 1 nd nd
Rwanda nd nd nd nd 8 27 5 22 nd nd
Zimbabwe 9 nd nd nd nd nd nd nd 4 nd
No new cases
Botswana nd nd nd nd nd nd nd nd nd nd
Burundi nd nd nd nd nd nd nd nd nd nd
Ethiopia nd nd nd nd nd nd nd nd nd nd
Namibia nd nd nd nd nd nd nd nd nd nd
Swaziland nd nd nd nd nd nd nd nd nd nd
Total 592 606 619 669 750 655 514 580 727 486
nd, no data reported
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Bank and have initiated the ﬁrst phase of a PATTEC project. 
In addition, four countries in the Kwando/Zambezi region 
have begun PATTEC activities, with very encouraging results.
The Next Steps
Integration of activities. The challenge for the immediate 
future is to avoid repeating past mistakes, and to achieve 
cost-effective, sustainable HAT surveillance and control. 
Sustainability can only be achieved through an integration 
of activities in a strengthened health system able to face 
such responsibilities. The current approach should include 
specialised teams and health care systems, rather than falling 
back on the former debate between the value of specialised 
teams or primary health care. In other words, specialised 
teams and primary health care need to work together 
synergistically [7]. 
But integration is not a simple delegation process. Major 
responsibilities cannot simply be passed on to the existing 
health services of remote rural areas inappropriately trained 
and equipped to handle HAT control. Integration must 
mean the active participation of a strengthened health system 
capable of implementing surveillance and control activities, 
buttressed by specialised HAT national staff. Unfortunately, 
the existing tools limit the full participation of the health 
care system staff in controlling the disease. The two main 
technical bottlenecks are the lack of a sensitive and speciﬁc 
diagnostic test and of a new drug that is cheap, safe, and easy 
to administer.
New approaches to surveillance and control. To 
sustain recent achievements in HAT control and the 
epidemiological downward trend, it will be necessary to 
develop a novel approach for surveillance and control 
adapted to the new requirements. This approach consists of 
an integration process involving national health care systems. 
Implementation, however, will require better tools than those 
presently available for diagnosis and treatment. Such a health 
systems–based approach may be adequate for areas affected 
by T. b. gambiense, but in areas affected by T. b. rhodesiense,
disease control cannot rely exclusively on human health 
services and will have to involve veterinary and entomological 
services as well.
Developing new diagnostic tools. Attempts to identify new 
antigens should result in more speciﬁc and sensitive tests for 
serodiagnosis of the disease, while changes in test format (i.e., 
the development of non-invasive saliva tests [8]) should result 
in more user-friendly tests. Much progress has been made in 
the development of molecular tools. Speciﬁc genes for both 
T. b. gambiense and T. b. rhodesiense have been identiﬁed [9–
11] for PCR-based detection of infection. Molecular dipstick 
tests allow easier reading of the PCR result [12], and the ﬁrst 
results using loop-mediated isothermal ampliﬁcation [13] are 
encouraging.
Disease bio-markers are being investigated using 
proteomics, such as surface-enhanced laser desorption/
ionisation time-of-ﬂight mass spectrometry (SELDI-ToF-
MS) [14]. However, these newly developed techniques, 
claimed to be substantially more sensitive and speciﬁc than 
those available in the ﬁeld today, often rely on complicated 
equipment. As a result, the test protocols are not compatible 
with prevailing conditions at HAT treatment centres in 
rural Africa. WHO has established a collaboration with the 
Foundation for Innovative New Diagnostics (http://www.
ﬁnddiagnostics.org/) to develop new simple diagnostic tools 
for the control of HAT that meet the requirements of a 
sustainable elimination approach. The desired characteristics 
of a new test were deﬁned as being “ready for use”, stable at 
room temperature, and affordable by national health systems. 
The new test should provide an uncontroversial diagnosis of 
both forms of the disease and require minimum training and 
equipment to allow its execution by any health worker.
Developing new tools for determining stage of disease. As
long as there is no safe and effective drug available to treat 
both stages of the disease, determining disease stage will 
remain necessary. Some progress has been made through 
the development of a point-of-care card agglutination test 
for immunoglobulin M quantiﬁcation in cerebrospinal 
ﬂuid [15]. Although this test appears highly promising in 
establishing central nervous system involvement, its accuracy 
and feasibility in the ﬁeld still need to be ascertained. The 
study of anti-neuroﬁlament and anti-galactocerebrosides 
antibodies [16] may open new avenues for staging the 
disease. Unfortunately, all these techniques continue to 
require a lumbar puncture. Stage markers in other body 
ﬂuids such as serum, urine, or saliva could become ideal tests 
to avoid the invasive procedure of a lumbar puncture, but 
remain to be identiﬁed.
Another possible technique for the diagnosis of central 
nervous system involvement is the measurement of sleep-
onset rapid eye movement by polysomnography, a method 
that involves assessing the sleep pattern of patients [17]. 
However, although it is not invasive, polysomnography has 
not yet been proven to be universally accurate. Obviously, 
much work still needs to be done to make improved staging 
tests available to health workers in endemic areas.
Advances in drug development. Eﬂornithine was developed 
over 20 years ago, and was registered for the treatment 
of gambiense disease in 1990. While the drug is safer than 
melarsoprol [18], eﬂornithine does have side effects: fever, 
unusual bleeding and weakness, diarrhoea, nausea, stomach 
doi:10.1371/journal.pmed.0050055.g003
Figure 3. Map of Africa Showing the Epidemiological Status of 
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pain, and vomiting are common, while rarer side effects such 
as convulsions, loss of hearing, hair loss, headache, anaemia, 
leucopenia, and thrombocytopenia have also been observed 
[19]. The administration of eﬂornithine, which requires 
multiple daily infusions, limits its use in the context of rural 
Africa, despite the determination of some programmes to use 
it as a ﬁrst-line drug. 
Recently a short-course melarsoprol treatment was 
developed [20,21]. Unfortunately, it does not provide a 
safer treatment; however, it has substantially reduced the 
hospitalisation time of patients and as a consequence the cost 
of treatment.
With the development of parasite resistance to some 
of the available drugs [22], a number of studies have 
attempted to combine existing drugs to overcome treatment 
failures [23,24]. A clinical trial, sponsored by Médecins 
sans Frontières-Holland, the Drugs for Neglected Diseases 
Initiative,  and the UNICEF-UNDP-World Bank-WHO Special 
Programme for Research and Training in Tropical Diseases, 
is currently ongoing to test a combination of eﬂornithine 
and nifurtimox, the latter being a drug registered for the 
treatment of American trypanosomiasis (Chagas disease). The 
aim of the study is not only to improve efﬁcacy and simplify 
administration, which would contribute to easier ﬁeld use and 
reduce cost, but also to ﬁnd a way to avoid the development 
of resistant strains to eﬂornithine. Such combination 
therapy remains far from ideal, since it continues to require 
intravenous administration with costly and complicated 
logistics and skilled staff. Furthermore this combination will 
only be effective for T. b. gambiense, and would certainly not 
be safe enough to be used in ﬁrst-stage patients; thus it will 
not help in avoiding the risky staging process.
A new oral drug called DB289 is in the ﬁnal clinical trial 
phase. Given its oral administration, it should be considered 
an important step forward. Unfortunately, the drug requires 
ten days of treatment, twice a day, and is only effective in the 
ﬁrst stage. Consequently, DB289 cannot be considered a new 
drug that would be a major advance in control of HAT.
The major challenge in developing a new drug that can 
ensure sustainable disease control will be to ﬁnd a safe and 
affordable, orally administered drug that is effective against 
both forms of the disease, in both disease stages, and that 
does not require any particular skills or care to administer. 
The ideal regimen should not last more than a few days, thus 
making it manageable by peripheral health staff in an out-
patient context.
Advances in vector control. Current vector control 
interventions involve the use of insecticides (through the 
sequential aerosol spraying technique, insecticide-treated 
targets [25], or insecticide-treated animals [26,27]); the use 
of traps [28,29]; and the sterile insect technique (SIT) [30].
The sequential aerosol technique, which uses extremely low 
concentration of insecticide through several consecutive aerial 
sprayings, can effectively clear large areas of tsetse ﬂies in a 
relatively short time, but it is expensive and requires substantial 
economic and infrastructure support. Pour-ons or selective 
spraying application of insecticides to animals on which tsetse 
feed are another effective means of vector control.
Odour-baited targets or traps have been used in many 
countries to effectively suppress tsetse population. The 
relative low cost and simplicity of the traps or targets 
recommends them for use by local communities, but they are 
applied on a scale so small that control efforts are bound to 
be frustrated by re-invasion.
While effective baits have been developed for savannah 
tsetse, to date no such baits exist for riverine tsetse, which are 
major vectors of HAT. However, research continues in an 
attempt to develop effective baits for the latter species.
The SIT, which involves the release of laboratory-reared 
and sterilised males to compete with wild males so that 
females inseminated by them produce no offspring, has 
been effectively used for eradication of tsetse (G. austeni), for 
example, in Unguja Island in Zanzibar [30]. The cost of SIT 
is, however, exorbitant. The feasibility of this costly approach 
in areas where multiple species are present remains doubtful 
[31].
The recent availability of genomics of tsetse-symbiotic 
bacteria [32] is of interest since in the absence of their gut 
ﬂora, tsetse ﬂies are severely impaired in their longevity 
and reproduction. Two bacteria have been implicated in 
modifying vector competence of their host, and a third 
symbiont can confer mating sterility. However, further 
research is needed to turn such new knowledge into practical 
use for disease control.
Despite the considerable progress made in controlling 
the vector, an ideal methodology easily accessible to the 
population at risk still does not exist.
Conclusion
While the number of new detected cases of HAT is falling, 
sleeping sickness could suffer the “punishment of success,” 
receiving lower priority by public and private health 
institutions with the consequent risk of losing the capacity 
to maintain disease control. While waiting for new tools 
for sleeping sickness control, the greatest challenge for the 
coming years will be to increase and sustain the current 
control efforts using existing tools. Effective surveillance 
and control followed by good reporting will be crucial. 
Furthermore, advocacy in endemic countries should continue 
to be maintained in the face of decreasing cases reported; 
sleeping sickness should retain its high priority with health 
policy makers and planners. Research must be encouraged 
doi:10.1371/journal.pmed.0050055.g004
Figure 4. T. b. gambiense: Comparative Evolution Curves between 
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to resolve the technical issues preventing the development 
of a new approach to surveillance and control that could be 
sustained by countries themselves.
Since elimination of the disease has been considered 
feasible, WHO will adopt the conclusions of countries where 
HAT is endemic, who have demonstrated that: (1) the 
participation of existing health systems is not only desirable 
but essential for surveillance and control sustainability; 
(2) the development of new diagnostic tools and drugs is 
crucial to guarantee the effective participation of existing 
health structures; and (3) the maintenance of a specialised 
central structure at national level is necessary to ensure the 
coordination and overall technical assistance needed. In that 
context, WHO is ready to take up the challenge and continue 
to lead countries, supporting and coordinating the work of all 
the actors involved.  
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